Company / PP&E (Net)
Krystal Biotech, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$150.8M
FY2025
5-year range
$112.4M / $161.7M
FY2021-FY2025
Trend
-2.8%
vs FY2024
Sector context
#34 of 193
Health Care
What the data says
Krystal Biotech, Inc.'s pp&e (net) of $151M is higher than 82% of companies in the Health Care sector (FY2025). PP&E (Net) has declined for 3 consecutive years, from $162M in FY2022 to $151M in FY2025.
Based on SEC 10-K filings.
$151M in FY2025 with a 5-year CAGR of +37.3%. Top quartile in the Health Care sector.
Declined from $161M to $151M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -2.3%
- 5-Year CAGR
- +37.3%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 193This company $150.8M Sector average $777.6M
▼
-80.6% below sector average
Key checks
Key Insights
- Krystal Biotech, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of +37.3%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 2.8% year-over-year.
- Ranks #34 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $150.8M | -2.8% |
| FY2024 | $155.2M | -3.7% |
| FY2023 | $161.2M | -0.3% |
| FY2022 | $161.7M | +43.9% |
| FY2021 | $112.4M | +263.9% |
| FY2020 | $30.9M | +264.3% |
| FY2019 | $8.5M | +181.2% |
| FY2018 | $3.0M | +1407.0% |
| FY2017 | $200.0K | +1438.5% |
| FY2016 | $13.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026